SLNO
Price:
$57.78
Market Cap:
$2.49B
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.[Read more]
Industry
Biotechnology
IPO Date
2014-11-13
Stock Exchange
NASDAQ
Ticker
SLNO
According to Soleno Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -20.71. This represents a change of 12.29% compared to the average of -18.44 of the last 4 quarters.
The mean historical PE Ratio of Soleno Therapeutics, Inc. over the last ten years is -3.56. The current -20.71 PE Ratio has changed 58.07% with respect to the historical average. Over the past ten years (40 quarters), SLNO's PE Ratio was at its highest in in the December 2018 quarter at 36.66. The PE Ratio was at its lowest in in the December 2023 quarter at -30.63.
Average
-3.56
Median
-1.10
Minimum
-17.03
Maximum
-0.14
Discovering the peaks and valleys of Soleno Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.98%
Maximum Annual PE Ratio = -0.14
Minimum Annual Increase = -90.69%
Minimum Annual PE Ratio = -17.03
Year | PE Ratio | Change |
---|---|---|
2023 | -17.03 | 1.98% |
2022 | -0.82 | -26.04% |
2021 | -1.11 | -85.92% |
2020 | -7.86 | 181.25% |
2019 | -2.79 | 3.91% |
2018 | -2.69 | 160.78% |
2017 | -1.03 | -0.93% |
2016 | -1.04 | -5.02% |
2015 | -1.10 | 702.63% |
2014 | -0.14 | -90.69% |
The current PE Ratio of Soleno Therapeutics, Inc. (SLNO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.32
5-year avg
-5.92
10-year avg
-3.56
Soleno Therapeutics, Inc.’s PE Ratio is less than Annexon, Inc. (-6.12), less than Icosavax, Inc. (-15.78), less than VectivBio Holding AG (-7.94), less than Bolt Biotherapeutics, Inc. (-0.34), less than Lyra Therapeutics, Inc. (-0.13), less than Pulmatrix, Inc. (-2.31), less than Capricor Therapeutics, Inc. (-0.05), less than Akari Therapeutics, Plc (-0.81), less than Diffusion Pharmaceuticals Inc. (444.81), less than Onconova Therapeutics, Inc. (-1.15), less than Catalyst Biosciences, Inc. (-4.80), less than Bio-Path Holdings, Inc. (-0.24), less than Moleculin Biotech, Inc. (-0.34), less than Day One Biopharmaceuticals, Inc. (-15.73), less than Acumen Pharmaceuticals, Inc. (-1.74), less than X4 Pharmaceuticals, Inc. (-4.05), less than Inozyme Pharma, Inc. (-1.84), less than Applied Molecular Transport Inc. (-0.43), less than Aileron Therapeutics, Inc. (-1.83), less than Benitec Biopharma Inc. (-5.35),
Company | PE Ratio | Market cap |
---|---|---|
-6.12 | $547.89M | |
-15.78 | $769.04M | |
-7.94 | $1.06B | |
-0.34 | $22.14M | |
-0.13 | $12.37M | |
-2.31 | $22.35M | |
-0.05 | $846.65M | |
-0.81 | $18.72M | |
444.81 | $8.98M | |
-1.15 | $20.90M | |
-4.80 | $19.42M | |
-0.24 | $3.53M | |
-0.34 | $8.20M | |
-15.73 | $1.38B | |
-1.74 | $142.39M | |
-4.05 | $57.64M | |
-1.84 | $180.51M | |
-0.43 | $11.01M | |
-1.83 | $53.51M | |
-5.35 | $243.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Soleno Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Soleno Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Soleno Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Soleno Therapeutics, Inc. (SLNO)?
What is the highest PE Ratio for Soleno Therapeutics, Inc. (SLNO)?
What is the 3-year average PE Ratio for Soleno Therapeutics, Inc. (SLNO)?
What is the 5-year average PE Ratio for Soleno Therapeutics, Inc. (SLNO)?
How does the current PE Ratio for Soleno Therapeutics, Inc. (SLNO) compare to its historical average?